Chemical modification of proteins by lipids in diabetes

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 9, 2003, Pages 1159-1165

  Baynes, John W ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

ELISA; Glycation; Glycoxidation; Lipid peroxidation; Lipoxidation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; LIPID; PLASMA PROTEIN;

AGE; BIOSYNTHESIS; CHEMICAL MODIFICATION; CLINICAL LABORATORY; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY DISEASE; LIPID OXIDATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; REVIEW;

ALBUMINS; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPID PEROXIDATION; LIPOXYGENASE;

EID: 0142029557     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.179     Document Type: Review

References (47)

1. Baynes JW, Thorpe SR. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003. In press.
2. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56:1-21.
3. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Mad 2000; 28:1708-16.
4. Spiteller G. Lipid peroxidation in aging and age-dependent diseases. Exp Gerontol 2001; 36:1425-57.
5. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11:93-102.
6. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993; 329:977-86.
7. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS). Br Med J 1998; 316:823-8.
8. Glomb MA, Pfahler C. Amides are novel protein modifications formed by physiological sugars. J Biol Chem 2001; 276:41638-47.
9. Biemel KM, Friedl DA, Lederer MO. Identification and quantification of major maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound. J Biol Chem 2002; 277: 24907-15.
10. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine-and Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem J 2002; 364(Pt 1):1-14.
11. Ahmed N, Thornalley PJ. Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J 2002; 364(Pt 1):15-24.
12. E-(carboxymethyl lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271:9982-6.
13. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Biol Chem 2000; 275:21177-84.
14. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61:939-50.
15. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51:2826-32.
16. Alderson NA, Chachich ME, Youssef NN, Nachtigal M, Beattie RJ, Thorpe SR, et al. Pyridoxamine limits dyslipidemia, hypertension and early nephropathy in obese Zucker (fatty) rats. Kidney Int 2003; 63:2123-33.
17. Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW. The role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 2003. In press.
18. Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991; 87:1910-5.
19. Baynes JW, Thorpe SR. The role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48:1-9.
20. Izuhara Y, Miyata T, Ueda Y, Suzuki D, Asahi K, Inagi R, et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant 1999; 14:576-80.
21. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267:5133-8.
22. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Mad 1991; 325:836-42.
23. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46:216-22.
24. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, Baynes JW. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 1998; 54: 1290-5.
25. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Int 2001; Suppl 78:S25-31.
26. Weiss MF, Erhard P, Kader-Attia FA, Wu YC, Deoreo PB, Araki A, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000; 57:2571-85.
27. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62:301-10.
28. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 2003; 52: 163-7.
29. E-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1998; 21:1997-2002.
30. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KF. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46:661-5.
31. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001; 24:1620-3.
32. Sebekova K, Kupcova V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J Hepatol 2002; 36:66-71.
33. Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 1998; 244:45-9.
34. E-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford) 2003. In press.
35. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997; 94:13915-20.
36. Bar KJ, Franke S, Wenda B, Muller S, Kientsch-Engel R, Stein G, et al. Pentosidine and N(varepsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 2003; 24:333-8.
37. Sebekova K, Krajcoviova-Kudlackova M, Schinzel R, Faist V, Klvanova J, Heidland A. Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. Eur J Nutr 2001; 40:275-81.
38. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8:337-46.
39. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99:15596-601.
40. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14:728-31.
41. Mitsuhashi T, Vlassara H, Founds HW, Li YM. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J Immunol Methods 1997; 207:79-88.
42. Fu S, Fu MX, Baynes JW, Thorpe SR, Dean RT. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins. Biochem J 1998; 330 (Pt 1):233-9.
43. Dorrian CA, Cathcart S, Clausen J, Shapiro D, Dominiczak MH. Factors in human serum interfere with the measurement of advanced glycation endproducts. Cell Mol Biol (Noisy-le-grand) 1998; 44:1069-79.
44. Shibayama R, Araki N, Nagai R, Horiuchi S. Autoantibody against Nε-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Diabetes 1999; 48:1842-9.
45. Nicoloff G, Baydanoff S, Petrova Ch, Christova P. Antibodies to advanced glycation end products in children with diabetes mellitus. Vascul Pharmacol 2002; 39:39-45.
46. Turk Z, Ljubic S, Turk N, Benko B. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta 2001; 303:105-15.
47. Krajcovicova-Kudlackova M, Sebekova K, Schinzel R, Klvanova J. Advanced glycation end products and nutrition. Physiol Res 2002; 51:313-6.